Cytokine Signalling Forum

Publications




Romatoid Artrit de Januz Kinaz İnhibitörü Tofasitinibin Preklinikten Kliniğe Geçişi

Dowty M, Jesson MI, Ghosh S, et al. - J Pharmacol Exp Ther. 2013. DOI:10.1124/jpet.113.209304

Preclinical studies can provide insight into mechanisms of efficacy and optimal dosing regimens. In this study, Dowty et al. compare the pharmacokinetic / pharmacodynamic profiles of tofacitinib in a murine arthritis model and in patients with rheumatoid arthritis from tofacitinib clinical trials. The main driver of efficacy in both preclinical murine arthritis models and clinical RA was found to be inhibition of JAK1 heterodimer signalling, where total drug exposure (Cave) was a predictor of projected efficacy. The authors conclude that continuous or high levels of JAK1 inhibition are not required for effective modulation of inflammation, which may allow for short periods of drug absence.

Keywords: JAK, Tofacitinib, Preclinical, PK-PD

Access original article via Pubmed

Upload date: January 2014

Translated by: Bahtiyar Toz

Article image